928 Phase I trial of the topoisomerase I inhibitor GG211 as a 72-hour infusion by O’Dwyer, P., Pas-Arez, L., Kunka, R., DeMaria, D., Cassidy, J., Kaye, S., DePee, S., Littlefield, D., Selinger, K., Beranek, P., Graham, J., Wissel, P.

Get full text